{
    "2021-11-03": [
        [
            {
                "time": "",
                "original_text": "公募基金持股市值创新高，社保显著加仓周期股（附表）",
                "features": {
                    "keywords": [
                        "公募基金",
                        "持股市值",
                        "创新高",
                        "社保",
                        "加仓",
                        "周期股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "周期股"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中信建投：维持智飞生物(300122.SZ)“买入”评级 业绩符合预期 重磅品种放量可期",
                "features": {
                    "keywords": [
                        "中信建投",
                        "智飞生物",
                        "买入评级",
                        "业绩",
                        "重磅品种",
                        "放量"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业：疫苗板块高景气有望延续",
                "features": {
                    "keywords": [
                        "医药行业",
                        "疫苗板块",
                        "高景气",
                        "延续"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物上市公司2021年三季报小结：板块业绩增速继续稳定 自下而上寻找专精特新",
                "features": {
                    "keywords": [
                        "医药生物",
                        "上市公司",
                        "三季报",
                        "板块业绩",
                        "增速稳定",
                        "专精特新"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}